Finally, T2DM management should be individualized to minimize hypoglycemia and falls and to avoid agents that may have negative skeletal effects (eg, insulin therapy, sulfonylureas, thiazolidinediones, and canagliflozin). The gene discussed is INS; the disease is type 2 diabetes mellitus.